Merckle Report issue

For profit Phase 1 Phase 3
Founded: Ulm Germany (1881)
Status: Acquired by Recordati (2005)

Organization Overview

First Clinical Trial
2009
NCT02592031
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2014

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Merckle GmbH

Active Ingredients

Drugs in Phase 3 Trials (1)

Filgrastim (neupogen) (3 trials)

Drugs in Phase 1 Trials (2)

follitropin alfa (Gonal-F) (1 trial)

goserelin (zoladex) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Aggression (Phase 3)

Lymphoma (Phase 3)

Lymphoma, B-Cell (Phase 3)

Lymphoma, Non-Hodgkin (Phase 3)

Neuroectodermal Tumors, Primitive, Peripheral (Phase 1)

Neutropenia (Phase 3)

Rhabdomyosarcoma (Phase 1)

Sarcoma, Ewing (Phase 1)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 4
  • # of Trial APIs: 3